Methylation status of HPV16 E2-binding sites classifies subtypes of HPV-associated oropharyngeal cancers

Cancer

Volumn 121, Issue 12, 2015, Pages 1966-1976

  Reuschenbach, Miriam ^a,b   Huebbers, Christian U ^c   Prigge, Elena Sophie ^a,b   Bermejo, Justo Lorenzo ^d   Kalteis, Martin S ^a,b   Preuss, Simon F ^e   Seuthe, Inga M C ^e   Kolligs, Jutta ^c   Speel, Ernst Jan M ^f   Olthof, Nadine ^f   Kremer, Bernd ^f   Wagner, Steffen ^g   Klussmann, Jens P ^g   Vinokurova, Svetlana ^a,b   Von Knebel Doeberitz, Magnus ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

E2 binding sites; human papillomavirus (HPV); methylation; oropharyngeal cancer; upstream regulatory region

Indexed keywords

HUMAN PAPILLOMAVIRUS E2 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; DNA BINDING PROTEIN; E2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ADULT; ARTICLE; BINDING SITE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; E2 GENE; FEMALE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN METHYLATION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; CLASSIFICATION; DNA METHYLATION; GENETICS; METABOLISM; MIDDLE AGED; OROPHARYNX TUMOR; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; TUMOR CELL LINE; VIROLOGY;

BINDING SITES; CELL LINE, TUMOR; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84930375496     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29315     Document Type: Article

References (30)

1. zur Hausen H,. Papillomaviruses in the causation of human cancers- A brief historical account. Virology. 2009; 384: 260-265.
2. Chaturvedi AK,. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010; 46 (suppl 4): S20-S26.
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
4. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM,. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63: 1129-1136.
5. Boyer SN, Wazer DE, Band V,. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996; 56: 4620-4624.
6. Doorbar J,. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110: 525-541.
7. Thierry F,. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology. 2009; 384: 375-379.
8. Romanczuk H, Thierry F, Howley PM,. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol. 1990; 64: 2849-2859.
9. Steger G, Corbach S,. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J Virol. 1997; 71: 50-58.
10. Rapp B, Pawellek A, Kraetzer F, et al., Cell-type-specific separate regulation of the E6 and E7 promoters of human papillomavirus type 6a by the viral transcription factor E2. J Virol. 1997; 71: 6956-6966.
11. Doeberitz Mv, Vinokurova S,. Host factors in HPV-related carcinogenesis: cellular mechanisms controlling HPV infections. Arch Med Res. 2009; 40: 435-442.
12. Stubenrauch F, Lim HB, Laimins LA,. Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31. J Virol. 1998; 72: 1071-1077.
13. Dowhanick JJ, McBride AA, Howley PM,. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol. 1995; 69: 7791-7799.
14. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM,. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J. 2000; 19: 5762-5771.
15. Pett M, Coleman N,. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007; 212: 356-367.
16. Vinokurova S, Wentzensen N, Kraus I, et al., Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008; 68: 307-313.
17. Chaiwongkot A, Vinokurova S, Pientong C, et al., Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int J Cancer. 2013; 132: 2087-2094.
18. Olthof NC, Speel EJ, Kolligs J, et al., Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS One. 2014; 9: e88718.
19. Mooren JJ, Kremer B, Claessen SM, et al., Chromosome stability in tonsillar squamous cell carcinoma is associated with HPV16 integration and indicates a favorable prognosis. Int J Cancer. 2013; 132: 1781-1789.
20. Durst M, Kleinheinz A, Hotz M, Gissmann L,. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol. 1985; 66 (pt 7): 1515-1522.
21. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM,. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol. 1987; 61: 962-971.
22. Akagi K, Li J, Broutian TR, et al., Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014; 24: 185-199.
23. Thain A, Jenkins O, Clarke AR, Gaston K,. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J Virol. 1996; 70: 7233-7235.
24. Vinokurova S, von Knebel Doeberitz M,. Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS One. 2011; 6: e24451.
25. Bhattacharjee B, Sengupta S,. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology. 2006; 354: 280-285.
26. Olthof NC, Huebbers CU, Kolligs J, et al., Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int J Cancer. 2015; 136: E207-E218.
27. Bihl MP, Foerster A, Lugli A, Zlobec I,. Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J Transl Med. 2012; 10: 173.
28. Van Tine BA, Kappes JC, Banerjee NS, et al., Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol. 2004; 78: 11172-11186.
29. Peter M, Stransky N, Couturier J, et al., Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol. 2010; 221: 320-330.
30. Kostareli E, Holzinger D, Bogatyrova O, et al., HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest. 2013; 123: 2488-2501.